Chapter 6 Neuropeptides and Their Processing: Targets for Drug Design

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Annual Reports in Medicinal Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0065-7743(08)61154-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Vasopressin antagonist analogs modified at position 7.

  2009cited by this paper
• Comparative biological activities of potent analogues of alpha-melanotropin. Effect of nonaromatic and para substituted aromatic amino acids at position 7.

  2009cited by this paper
• Plasma oxytocin concentrations in man after different routes of administration of synthetic oxytocin.

  2009cited by this paper
• Effect of captopril (a converting enzyme inhibitor) on blood-brain barrier permeability and cerebral blood flow in normotensive rats.

  1987cited by this paper
• Pharmacological studies of somatostatin and somatostatin-analogues: therapeutic advances and perspectives.

  1987cited by this paper
• Degradation of Luteinizing Hormone‐Releasing Hormone by Neuroblastoma Cells and Their Membrane: Evidence for the Involvement of a Thiol Protease and Angiotensin‐Converting Enzyme

  1987cited by this paper
• Problems with peptides

  1987cited by this paper
• A novel serine protease (IRCM-serine protease 1) from porcine neurointermediate and anterior pituitary lobes. Isolation, polypeptide chain structure, inhibitor sensitivity, and substrate specificity with fluorogenic peptide substrates.

  1986cited by this paper
• Preferential action of rat brain cathepsin B as a peptidyl dipeptidase converting pro-opioid oligopeptides.

  1986cited by this paper
• Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues.

  1986cited by this paper
• Study of an octadecaneuropeptide derived from diazepam binding inhibitor (DBI): biological activity and presence in rat brain.

  1986cited by this paper
• ACTH and attention in humans: a review.

  1986cited by this paper
• Opioid and other peptides as inhibitors of leumorphin (dynorphin B-29) converting activity.

  1986cited by this paper
• Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease

  1986cited by this paper
• Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats.

  1986cited by this paper
• Thyrotropin-releasing hormone precursor: characterization in rat brain.

  1986cited by this paper
• The processing of peptide precursors

  1986cited by this paper
• Carboxyl-modified amino acids and peptides as protease inhibitors.

  1986cited by this paper
• Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons.

  1986cited by this paper
• Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin.

  1986cited by this paper
• Antagonists of substance P. Further modifications of substance P antagonists obtained by replacing either positions 7, 9 or 7, 8 and 11 of SP with D-amino acid residues.

  1986cited by this paper
• Computer-aided, systematic search of peptide conformations constrained by NMR data.

  1986cited by this paper
• Design and synthesis of antagonists of substance P.

  1986cited by this paper
• Characterization of aminopeptidases responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies.

  1986cited by this paper
• Distribution of immunoreactive melanin-concentrating hormone in the central nervous system of the rat.

  1986cited by this paper
• Inhibition of serine proteases by peptidyl fluoromethyl ketones.

  1986cited by this paper
• Central nervous system effects of peptides, 1980-1985: a cross-listing of peptides and their central actions from the first six years of the journal Peptides.

  1986cited by this paper
• Analgesis and convulsant effects of guanidinoethylmercaptosuccinic acid (GEMSA) — A potent enkephalin convertase inhibitor

  1986cited by this paper
• Involvement of the central serotoninergic system in the changes of leu-enkephalin level in discrete rat brain areas.

  1986cited by this paper
• Enkephalin-degrading dipeptidylaminopeptidase: characterization of the active site and selective inhibition.

  1986cited by this paper
• Inhibition of Met5-enkephalin-Arg6-Phe7 degradation by inhibitors of dipeptidyl carboxypeptidase.

  1986cited by this paper
• Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor.

  1986cited by this paper
• Chronic haloperidol and clozapine differentially affect dynorphin peptides and substance P in basal ganglia of the rat.

  1986cited by this paper
• The effects of aging on molecular forms of beta- and gamma-endorphins in rat hypothalamus.

  1986cited by this paper
• Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.

  1986cited by this paper
• Growth hormone release in man induced by galanin, a new hypothalamic peptide.

  1986cited by this paper
• An endopeptidase associated with bovine neurohypophysis secretory granules cleaves pro-ocytocin/neurophysin peptide at paired basic residues.

  1986cited by this paper
• A new approach to the oral administration of insulin and other peptide drugs.

  1986cited by this paper
• Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

  1986cited by this paper
• Synthesis of thyrotropin-releasing hormone analogues. 2. Tripeptides structurally greatly differing from TRH with high central nervous system activity.

  1986cited by this paper
• Haloperidol increases plasma beta endorphin-like immunoreactivity and cortisol in normal human males.

  1986cited by this paper
• Neuropeptide-specific peptidases: does brain contain a specific TRH-degrading enzyme?

  1986cited by this paper
• Neuroleptic treatment induces region-specific changes in levels of neurokinin A and substance P in rat brain.

  1986cited by this paper
• Research topics in the medicinal chemistry and molecular pharmacology of opioid peptides--present and future.

  1986cited by this paper
• Neuropeptides: multiple molecular forms, metabolic pathways, and receptors.

  1986cited by this paper
• A second isolate of HTLV-II associated with atypical hairy-cell leukemia.

  1986cited by this paper
• Isolation of angiotensin-converting enzyme inhibitor from porcine plasma.

  1986cited by this paper
• Synthesis and biological activity of substance P C-terminal hexapeptide analogues: structure-activity studies.

  1986cited by this paper
• Receptor-mediated peptide transport through the blood-brain barrier.

  1986cited by this paper
• Nomenclature for enkephalin degrading peptidases.

  1986cited by this paper
• Increased potency of antagonists of the luteinizing hormone releasing hormone which have D-3-Pal in position 6.

  1986cited by this paper
• Conformational analysis of cholecystokinin CCK26-33 and related fragments by 1H NMR spectroscopy, fluorescence-transfer measurements, and calculations.

  1986cited by this paper
• Inactivation and metabolism of neuropeptides.

  1986cited by this paper
• Identification and Initial Characterization of Adipokinetic Hormone‐Like Immunoreactive Peptides of Rat Origin

  1986cited by this paper
• Comparative Study of Intranasal, Subcutaneous and Intravenous Administration of Desamino-D-Arginine Vasopressin (DDAVP)

  1986cited by this paper
• Peptidyl carbamates incorporating amino acid isosteres as novel elastase inhibitors.

  1986cited by this paper
• Stimulation of gonadotropin release by a non-GnRH peptide sequence of the GnRH precursor.

  1986cited by this paper
• New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro.

  1986cited by this paper
• Precursors for peptide hormones share common secondary structures forming features at the proteolytic processing sites

  1986cited by this paper
• Purification and characterization of a paired basic residue-specific prohormone-converting enzyme from bovine pituitary neural lobe secretory vesicles.

  1986cited by this paper
• Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.

  1986cited by this paper
• Quantitative distribution of galanin-like immunoreactivity in the rat central nervous system.

  1986cited by this paper
• Hydrolysis of neo-kyotorphin (Thr-Ser-Lys-Tyr-Arg) and [Met]enkephalin-Arg6-Phe7 by angiotensin-converting enzyme from monkey brain.

  1986cited by this paper
• Analogues of substance P. Peptides containing D-amino acid residues in various positions of substance P and displaying agonist or receptor selective antagonist effects.

  1986cited by this paper
• Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system.

  1986cited by this paper
• Strategies for the inhibition of neuropeptide-metabolizing enzymes.

  1986cited by this paper
• Characterization of an enzyme that is capable of processing pro-gonadotropin-releasing hormone protein.

  1986cited by this paper
• Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.

  1986cited by this paper
• Problems with peptides — all that glisters is not gold

  1986cited by this paper
• Cerebellin-like peptide: A novel neurotransmitter?

  1986cited by this paper
• Immobilized enzymes in clinical medicine: an emerging approach to new drug therapies

  1986cited by this paper
• Impaired α‐carboxyamidation of gastrin in vitamin C‐deficient guinea pigs

  1986cited by this paper
• Membrane Structure of Substance P. II. Secondary Structure of Substance P, [9‐Leucine]substance P, and Shorter Segments in 2,2,2‐Trifluoroethanol, Methanol, and on Liposomes Studied by Circular Dichroism

  1986cited by this paper
• Chapter 6. Formation and Degradation of Neuropeptides

  1986cited by this paper
• Tripeptidyl carboxypeptidase activity of angiotensin I-converting enzyme in human tissues and fluids

  1986cited by this paper
• Membrane Structure of Substance P. III. Secondary Structure of Substance P in 2,2,2‐Trifluoroethanol, Methanol, and on Flat Lipid Membranes Studied by Infrared Spectroscopy

  1986cited by this paper
• Proteinkristallographie und Computer-Graphik – auf dem Weg zu einer planvollen Arzneimittelentwicklung

  1986cited by this paper
• Membrane Structure of Substance P. I. Prediction of Preferred Conformation, Orientation, and Accumulation of Substance P on Lipid Membranes†

  1986cited by this paper
• Pharmacology of enkephalinase inhibitors

  1986cited by this paper
• Intra-cerebroventricular captopril reduces plasma ACTH and vasopressin responses to hemorrhagic stress.

  1986cited by this paper
• An orally active inhibitor of renin.

  1986cited by this paper
• Highly selective agonists for substance P receptor subtypes.

  1986cited by this paper
• Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease.

  1986cited by this paper
• Patients with Alzheimer's disease show an increased content of 15 Kdalton somatostatin precursor and a lowered level of tetradecapeptide in their cerebrospinal fluid.

  1986cited by this paper
• Peptide hormone antagonists that are effective in vivo. Lessons from parathyroid hormone.

  1986cited by this paper
• Synthetic antagonists of the myometrial response to vasopressin and oxytocin.

  1986cited by this paper
• Kelatorphan: a full inhibitor of enkephalin degrading enzymes. Biochemical and pharmacological properties, regional distribution of enkephalinase in rat brain by use of a tritiated derivative.

  1985cited by this paper
• LHRH and analogs: contraceptive and therapeutic considerations.

  1985cited by this paper
• The design of metabolically-stable peptide analogs

  1985cited by this paper
• Serum luteinizing hormone-releasing hormone (LH-RH) and gonadotropic hormones in men after a bolus dose of LH-RH: comparison of different doses and routes of administration.

  1985cited by this paper
• Neuropharmacological Profile of Cholecystokinin‐like Peptides

  1985cited by this paper
• Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain.

  1985cited by this paper
• Pharmacokinetics and Bioavailability of Injected Glucagon: Differences Between Intramuscular, Subcutaneous, and Intravenous Administration

  1985cited by this paper
• Permeability of the blood-brain barrier

  1985cited by this paper
• Pharmacology of enkephalinase inhibitors

  1985cited by this paper
• Permeability of the blood-brain barrier to neuropeptides: the case for penetration.

  1985cited by this paper
• The regional distribution and the chemical, chromatographic, and immunologic characterization of motilin brain peptides: the evidence for a difference between brain and intestinal motilin-immunoreactive peptides

  1985cited by this paper
• Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men.

  1985cited by this paper
• New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties.

  1985cited by this paper
• Design of peptide hormone and neurotransmitter analogues

  1985cited by this paper

• ENKASTINES : AMADORI PRODUCTS WITH A SPECIFIC INHIBITING ACTION AGAINST ENDOPEPTIDASE - 24.11 - FROM STREPTOMYCES ALBUS AND BY SYNTHESIS

  2006cites this paper
• Third‐generation antidepressants

  1993cites this paper
• Development and testing of protocols for computer-aided design of peptide drugs, using oxytocin.

  1991cites this paper
• Recent developments in inhibiting cysteine and serine proteases.

  1990cites this paper
• Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).

  1989cites this paper